Figure 4.EGCG and ECG mediate lifespan extension dependent on PMK-1/p38 MAPK, SKN-1/NRF2, and DAF-16/FOXO. The representative outcome of lifespan assay of pmk-1 mutants treated with 0.1% DMSO versus 2.5 μM EGCG (A) or 2.5 μM ECG. (B) The representative outcome of lifespan assay of skn-1 mutants treated with 0.1% DMSO versus 2.5 μM EGCG (C) or 2.5 μM ECG. (D) The representative outcome of lifespan assay of daf-16 mutants treated with 0.1% DMSO versus 2.5 μM EGCG (E) or 2.5 μM ECG. (F) P-values are as indicated in the graphs. See Table 1 for corresponding detailed data and statistical analyses of lifespan assays.
